{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T11:47:10Z","timestamp":1790423230248,"version":"4.1.0"},"reference-count":102,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T00:00:00Z","timestamp":1776902400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["iLIVER"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.iliver.2026.100235","type":"journal-article","created":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T04:17:05Z","timestamp":1777609025000},"page":"100235","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Functional cure for chronic hepatitis B on hepatocellular carcinoma prevention: Evidence and clinical implications"],"prefix":"10.1016","volume":"5","author":[{"given":"Wen","family":"Kang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Shen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian-Ping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu-Ming","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1949-7737","authenticated-orcid":false,"given":"Yu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2573-5471","authenticated-orcid":false,"given":"Ye","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.iliver.2026.100235_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7774\/cevr.2020.9.1.1","article-title":"Hepatitis B vaccination and immunotherapies: an update","volume":"9","author":"Stasi","year":"2020","journal-title":"Clin Exp Vaccine Res"},{"issue":"3","key":"10.1016\/j.iliver.2026.100235_bib2","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"10.1016\/j.iliver.2026.100235_bib3","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1097\/CM9.0000000000002108","article-title":"Cancer statistics in China and United States, 2022: profiles, trends, and determinants","volume":"135","author":"Xia","year":"2022","journal-title":"Chin Med J"},{"issue":"1","key":"10.1016\/j.iliver.2026.100235_bib4","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1200\/JCO.2015.61.5724","article-title":"Infection and cancer: the case of hepatitis B","volume":"34","author":"Chan","year":"2016","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.iliver.2026.100235_bib5","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s41256-024-00345-2","article-title":"Assessing the impact of comorbid type 2 diabetes mellitus on the disease burden of chronic hepatitis B virus infection and its complications in China from 2006 to 2030: a modeling study","volume":"9","author":"Xie","year":"2024","journal-title":"Glob Health Res Pol"},{"issue":"6","key":"10.1016\/j.iliver.2026.100235_bib6","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1016\/j.bpg.2008.11.006","article-title":"Natural history: the importance of viral load, liver damage and HCC","volume":"22","author":"Wursthorn","year":"2008","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"10.1016\/j.iliver.2026.100235_bib7","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1200\/EDBK_200939","article-title":"Global epidemiology, prevention, and management of hepatocellular carcinoma","volume":"38","author":"Mak","year":"2018","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"3","key":"10.1016\/j.iliver.2026.100235_bib8","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/sj.bjc.6602333","article-title":"A meta-analysis of case-control studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma in China","volume":"92","author":"Shi","year":"2005","journal-title":"Br J Cancer"},{"issue":"3","key":"10.1016\/j.iliver.2026.100235_bib9","doi-asserted-by":"crossref","first-page":"605","DOI":"10.3350\/cmh.2022.0342","article-title":"Development of hepatocellular carcinoma in treated and untreated patients with chronic hepatitis B virus infection","volume":"29","author":"Lin","year":"2023","journal-title":"Clin Mol Hepatol"},{"issue":"6","key":"10.1016\/j.iliver.2026.100235_bib10","first-page":"1425","article-title":"Guidelines for the prevention and treatment of chronic hepatitis B (version 2022)","volume":"11","author":"You","year":"2023","journal-title":"J Clin Transl Hepatol"},{"issue":"2","key":"10.1016\/j.iliver.2026.100235_bib11","article-title":"Clinical outcomes of cessation of nucleoside\/nucleotide analogues in Chinese patients with HBeAg-negative chronic hepatitis","volume":"3","author":"Li","year":"2024","journal-title":"B iLIVER"},{"key":"10.1016\/j.iliver.2026.100235_bib12","first-page":"87","article-title":"Current perspectives on nucleos(t)ide analogue therapy for the long-term treatment of hepatitis B virus","volume":"14","author":"Broquetas","year":"2022","journal-title":"Hepat Med"},{"key":"10.1016\/j.iliver.2026.100235_bib13","doi-asserted-by":"crossref","first-page":"10411","DOI":"10.2147\/DDDT.S564254","article-title":"Pegylated interferon-\u03b1-induced functional cure for special populations with chronic hepatitis B virus infection: current trends, challenges and prospection","volume":"19","author":"Zhang","year":"2025","journal-title":"Drug Des Dev Ther"},{"issue":"Suppl 1","key":"10.1016\/j.iliver.2026.100235_bib14","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/jvh.13150","article-title":"Effects of pegylated interferon-\u03b1 based therapies on functional cure and the risk of hepatocellular carcinoma development in patients with chronic hepatitis B","volume":"26","author":"Ren","year":"2019","journal-title":"J Viral Hepat"},{"issue":"7","key":"10.1016\/j.iliver.2026.100235_bib15","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1002\/(SICI)1097-0142(19991001)86:7<1143::AID-CNCR7>3.0.CO;2-Z","article-title":"Age, gender, and local geographic variations of viral etiology of hepatocellular carcinoma in a hyperendemic area for hepatitis B virus infection","volume":"86","author":"Lee","year":"1999","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.iliver.2026.100235_bib16","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1007\/s10620-019-05537-2","article-title":"Disease burden of hepatocellular carcinoma: a global perspective","volume":"64","author":"Sayiner","year":"2019","journal-title":"Dig Dis Sci"},{"issue":"2","key":"10.1016\/j.iliver.2026.100235_bib17","doi-asserted-by":"crossref","first-page":"135","DOI":"10.3350\/cmh.2023.0412","article-title":"Comprehensive approach to controlling chronic hepatitis B in China","volume":"30","author":"Shan","year":"2024","journal-title":"Clin Mol Hepatol"},{"issue":"2","key":"10.1016\/j.iliver.2026.100235_bib18","doi-asserted-by":"crossref","first-page":"e180","DOI":"10.1016\/S2214-109X(19)30488-7","article-title":"Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis","volume":"8","author":"de Martel","year":"2020","journal-title":"Lancet Global Health"},{"issue":"1","key":"10.1016\/j.iliver.2026.100235_bib19","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/hep.26180","article-title":"Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection","volume":"58","author":"Hosaka","year":"2013","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.iliver.2026.100235_bib20","doi-asserted-by":"crossref","DOI":"10.1111\/jvh.70021","article-title":"Validation study of scores predicting hepatocellular carcinoma risk in chronic hepatitis B patients treated with nucleos(t)ide analogues","volume":"32","author":"Inoue","year":"2025","journal-title":"J Viral Hepat"},{"issue":"10","key":"10.1016\/j.iliver.2026.100235_bib21","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1111\/jvh.13572","article-title":"Efficacy of entecavir versus tenofovir in preventing hepatocellular carcinoma in patients with chronic hepatitis B with maintained virologic response","volume":"28","author":"Na","year":"2021","journal-title":"J Viral Hepat"},{"issue":"3","key":"10.1016\/j.iliver.2026.100235_bib22","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.jhep.2019.03.028","article-title":"A multicenter study of entecavir vs. tenofovir on prognosis of treatment-na\u00efve chronic hepatitis B in South Korea","volume":"71","author":"Kim","year":"2019","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.iliver.2026.100235_bib23","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.2208","article-title":"Liver cancer etiology in Asian subgroups and American Indian, black, Latino, and white populations","volume":"8","author":"Pinheiro","year":"2025","journal-title":"JAMA Netw Open"},{"issue":"17","key":"10.1016\/j.iliver.2026.100235_bib24","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1097\/CM9.0000000000002331","article-title":"Trends in mortality of liver disease due to hepatitis B in China from 1990 to 2019: findings from the global burden of disease study","volume":"135","author":"Cao","year":"2022","journal-title":"Chin Med J"},{"issue":"11","key":"10.1016\/j.iliver.2026.100235_bib25","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.45525","article-title":"Trends in hepatocellular carcinoma mortality rates in the US and projections through 2040","volume":"7","author":"Qiu","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"1","key":"10.1016\/j.iliver.2026.100235_bib26","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1159\/000530699","article-title":"HBV DNA integration into telomerase or MLL4 genes and TERT promoter point mutation as three independent signatures in subgrouping HBV-related HCC with distinct features","volume":"13","author":"Li","year":"2024","journal-title":"Liver Cancer"},{"issue":"3","key":"10.1016\/j.iliver.2026.100235_bib27","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1136\/gutjnl-2020-323153","article-title":"Hepatitis B virus integrations promote local and distant oncogenic driver alterations in hepatocellular carcinoma","volume":"71","author":"P\u00e9neau","year":"2022","journal-title":"Gut"},{"issue":"7","key":"10.1016\/j.iliver.2026.100235_bib28","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1136\/gutjnl-2023-330414","article-title":"HBV integrations reshaping genomic structures promote hepatocellular carcinoma","volume":"73","author":"Qian","year":"2024","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.iliver.2026.100235_bib29","doi-asserted-by":"crossref","first-page":"61","DOI":"10.2174\/1389202919666181002144336","article-title":"Profile of HBV integration in the plasma DNA of hepatocellular carcinoma patients","volume":"20","author":"Li","year":"2019","journal-title":"Curr Genom"},{"issue":"6","key":"10.1016\/j.iliver.2026.100235_bib30","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1002\/ijc.30547","article-title":"Distinct hepatitis B virus integration patterns in hepatocellular carcinoma and adjacent normal liver tissue","volume":"140","author":"Yang","year":"2017","journal-title":"Int J Cancer"},{"issue":"18","key":"10.1016\/j.iliver.2026.100235_bib31","doi-asserted-by":"crossref","first-page":"3225","DOI":"10.7150\/jca.26052","article-title":"Molecular characterization of HBV DNA integration in patients with hepatitis and hepatocellular carcinoma","volume":"9","author":"Yang","year":"2018","journal-title":"J Cancer"},{"issue":"2","key":"10.1016\/j.iliver.2026.100235_bib32","doi-asserted-by":"crossref","first-page":"509","DOI":"10.3350\/cmh.2024.0545","article-title":"Male preference for TERT alterations and HBV integration in young-age HBV-related HCC: implications for sex disparity","volume":"31","author":"Kim","year":"2025","journal-title":"Clin Mol Hepatol"},{"issue":"13","key":"10.1016\/j.iliver.2026.100235_bib33","doi-asserted-by":"crossref","first-page":"7056","DOI":"10.3390\/ijms22137056","article-title":"Distinct patterns of HBV integration and TERT alterations between in tumor and non-tumor tissue in patients with hepatocellular carcinoma","volume":"22","author":"Jang","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"9","key":"10.1016\/j.iliver.2026.100235_bib34","article-title":"Profiles of HBV DNA integration in humans with hepatitis B virus infection: insights for antiviral treatment","volume":"7","author":"Hui","year":"2025","journal-title":"JHEP Rep"},{"issue":"6","key":"10.1016\/j.iliver.2026.100235_bib35","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.29606","article-title":"Long-term antiviral therapy is associated with changes in the profile of transcriptionally active HBV integration in the livers of patients with CHB","volume":"96","author":"Wen","year":"2024","journal-title":"J Med Virol"},{"issue":"5","key":"10.1016\/j.iliver.2026.100235_bib36","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1136\/gutjnl-2023-330577","article-title":"Spatial transcriptomics reveals a low extent of transcriptionally active hepatitis B virus integration in patients with HBsAg loss","volume":"73","author":"Yu","year":"2024","journal-title":"Gut"},{"issue":"10","key":"10.1016\/j.iliver.2026.100235_bib37","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1111\/apt.17670","article-title":"Integrated HBV DNA and cccDNA maintain transcriptional activity in intrahepatic HBsAg-positive patients with functional cure following PEG-IFN-based therapy","volume":"58","author":"Gao","year":"2023","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.iliver.2026.100235_bib38","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.2147\/IJGM.S462844","article-title":"Impact of HBV integration on hepatocellular carcinoma after long-term antiviral therapy","volume":"17","author":"Wang","year":"2024","journal-title":"Int J Gen Med"},{"issue":"10","key":"10.1016\/j.iliver.2026.100235_bib39","doi-asserted-by":"crossref","first-page":"8419","DOI":"10.1002\/jcb.27050","article-title":"CRISPR\/Cas9-mediated knockout of HBsAg inhibits proliferation and tumorigenicity of HBV-positive hepatocellular carcinoma cells","volume":"119","author":"Song","year":"2018","journal-title":"J Cell Biochem"},{"issue":"2","key":"10.1016\/j.iliver.2026.100235_bib40","first-page":"1035","article-title":"HBsAg\/\u03b22GPI activates the NF-\u03baB pathway via the TLR4\/MyD88\/I\u03baB\u03b1 axis in hepatocellular carcinoma","volume":"40","author":"Jing","year":"2018","journal-title":"Oncol Rep"},{"issue":"5","key":"10.1016\/j.iliver.2026.100235_bib41","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.02731-21","article-title":"Hepatitis B virus-encoded HBsAg contributes to hepatocarcinogenesis by inducing the oncogenic long noncoding RNA LINC00665 through the NF-\u03baB pathway","volume":"10","author":"Ahluwalia","year":"2022","journal-title":"Microbiol Spectr"},{"issue":"1","key":"10.1016\/j.iliver.2026.100235_bib42","first-page":"118","article-title":"Hepatitis B virus surface antigen promotes stemness of hepatocellular carcinoma through regulating microRNA-203a","volume":"11","author":"Qin","year":"2023","journal-title":"J Clin Transl Hepatol"},{"issue":"4","key":"10.1016\/j.iliver.2026.100235_bib43","doi-asserted-by":"crossref","first-page":"741","DOI":"10.3390\/cells11040741","article-title":"Hepatitis B viral protein HBx and the molecular mechanisms modulating the hallmarks of hepatocellular carcinoma: a comprehensive review","volume":"11","author":"Sivasudhan","year":"2022","journal-title":"Cells"},{"issue":"5","key":"10.1016\/j.iliver.2026.100235_bib44","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1053\/j.gastro.2011.06.051","article-title":"A proinflammatory role for interleukin-22 in the immune response to hepatitis B virus","volume":"141","author":"Zhang","year":"2011","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.iliver.2026.100235_bib45","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1186\/s13046-022-02531-x","article-title":"Aerobic glycolysis enhances HBx-initiated hepatocellular carcinogenesis via NF-\u03baBp65\/HK2 signalling","volume":"41","author":"Chen","year":"2022","journal-title":"J Exp Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.iliver.2026.100235_bib46","doi-asserted-by":"crossref","DOI":"10.1002\/mco2.70121","article-title":"The malignant transformation of viral hepatitis to hepatocellular carcinoma: mechanisms and interventions","volume":"6","author":"Yuan","year":"2025","journal-title":"MedComm"},{"issue":"3","key":"10.1016\/j.iliver.2026.100235_bib47","doi-asserted-by":"crossref","first-page":"76","DOI":"10.3892\/mco.2025.2871","article-title":"Single-cell analysis reveals distinct immune characteristics of hepatocellular carcinoma in HBV-positive vs. HBV-negative cases","volume":"23","author":"Liu","year":"2025","journal-title":"Mol Clin Oncol"},{"issue":"11","key":"10.1016\/j.iliver.2026.100235_bib48","article-title":"Landscape of T-cell exhaustion heterogeneity and HBV integration in virus-related HCC revealed by whole-exome, transcriptome, and single-cell sequencing","volume":"7","author":"Lee","year":"2025","journal-title":"JHEP Rep"},{"issue":"1","key":"10.1016\/j.iliver.2026.100235_bib49","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1186\/s13046-023-02710-4","article-title":"Single-cell analysis reveals HBV-specific PD-1+CD8+ TRM cells in tumor borders are associated with HBV-related hepatic damage and fibrosis in HCC patients","volume":"42","author":"Liu","year":"2023","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.iliver.2026.100235_bib50","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-69522-w","article-title":"Detectable HBV DNA during nucleos(t)ide analogues stratifies predictive hepatocellular carcinoma risk score","volume":"10","author":"Kaneko","year":"2020","journal-title":"Sci Rep"},{"issue":"10","key":"10.1016\/j.iliver.2026.100235_bib51","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.7326\/M24-0384","article-title":"Viral load-based prediction of hepatocellular carcinoma risk in noncirrhotic patients with chronic hepatitis B: a multinational study for the development and external validation of a new prognostic model","volume":"177","author":"Kim","year":"2024","journal-title":"Ann Intern Med"},{"issue":"2","key":"10.1016\/j.iliver.2026.100235_bib52","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1097\/HEP.0000000000000752","article-title":"Chronic hepatitis B baseline viral load and on-treatment liver cancer risk: a multinational cohort study of HBeAg-positive patients","volume":"80","author":"Choi","year":"2024","journal-title":"Hepatology"},{"issue":"9","key":"10.1016\/j.iliver.2026.100235_bib53","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1111\/liv.13142","article-title":"Incidence of hepatocellular carcinoma in untreated subjects with chronic hepatitis B: a systematic review and meta-analysis","volume":"36","author":"Raffetti","year":"2016","journal-title":"Liver Int"},{"issue":"6","key":"10.1016\/j.iliver.2026.100235_bib54","doi-asserted-by":"crossref","first-page":"604","DOI":"10.3390\/ijerph13060604","article-title":"Analysis of risk factors associated with the development of hepatocellular carcinoma in chronic HBV-infected Chinese: a meta-analysis","volume":"13","author":"Lyu","year":"2016","journal-title":"Int J Environ Res Publ Health"},{"issue":"2","key":"10.1016\/j.iliver.2026.100235_bib55","doi-asserted-by":"crossref","first-page":"88","DOI":"10.21037\/hbsn.2018.11.20","article-title":"Association of family history with long-term prognosis in patients undergoing liver resection of HBV-related hepatocellular carcinoma","volume":"8","author":"Li","year":"2019","journal-title":"Hepatobiliary Surg Nutr"},{"issue":"1","key":"10.1016\/j.iliver.2026.100235_bib56","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1038\/s41467-021-22560-y","article-title":"An integrative analysis of the age-associated multi-omic landscape across cancers","volume":"12","author":"Chatsirisupachai","year":"2021","journal-title":"Nat Commun"},{"issue":"8","key":"10.1016\/j.iliver.2026.100235_bib57","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2024.110519","article-title":"Androgen receptor-induced molecules and androgen contribute synergistically to male-predominance of hepatocellular carcinoma","volume":"27","author":"Zhao","year":"2024","journal-title":"iScience"},{"issue":"2","key":"10.1016\/j.iliver.2026.100235_bib58","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.jcmgh.2022.10.009","article-title":"Sex differences in genomic features of hepatitis B-associated hepatocellular carcinoma with distinct antitumor immunity","volume":"15","author":"Xu","year":"2023","journal-title":"Cell Mol Gastroenterol Hepatol"},{"issue":"10","key":"10.1016\/j.iliver.2026.100235_bib59","article-title":"HBV-related HCC development in mice is STAT3 dependent and indicates an oncogenic effect of HBx","volume":"6","author":"Ringelhan","year":"2024","journal-title":"JHEP Rep"},{"issue":"4","key":"10.1016\/j.iliver.2026.100235_bib60","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1111\/j.1440-1746.2011.06695.x","article-title":"Natural history of chronic hepatitis B REVEALed","volume":"26","author":"Chen","year":"2011","journal-title":"J Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.iliver.2026.100235_bib61","doi-asserted-by":"crossref","first-page":"2965","DOI":"10.1002\/hep.32065","article-title":"HBV genotype: a significant risk factor in determining which patients with chronic HBV infection should undergo surveillance for HCC: the hepatitis B Alaska study","volume":"74","author":"McMahon","year":"2021","journal-title":"Hepatology"},{"issue":"5\/6","key":"10.1016\/j.iliver.2026.100235_bib62","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1159\/000355243","article-title":"Oxidative stress and epigenetic instability in human hepatocarcinogenesis","volume":"31","author":"Nishida","year":"2013","journal-title":"Dig Dis"},{"issue":"4","key":"10.1016\/j.iliver.2026.100235_bib63","first-page":"787","article-title":"Genetic polymorphism of MTHFR C677T influences susceptibility to HBV-related hepatocellular carcinoma in a Chinese population: a case-control study","volume":"63","author":"Qiao","year":"2017","journal-title":"Clin Lab"},{"issue":"2","key":"10.1016\/j.iliver.2026.100235_bib64","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1002\/hep.510300204","article-title":"Increased risk of hepatocellular carcinoma in male hepatitis B surface antigen carriers with chronic hepatitis who have detectable urinary aflatoxin metabolite M1","volume":"30","author":"Sun","year":"1999","journal-title":"Hepatology"},{"key":"10.1016\/j.iliver.2026.100235_bib65","doi-asserted-by":"crossref","first-page":"S126","DOI":"10.1016\/j.jhep.2005.11.026","article-title":"Assessment of liver fibrosis in co-infected patients","volume":"44","author":"Kelleher","year":"2006","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.iliver.2026.100235_bib66","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.jhep.2025.08.022","article-title":"Alcohol activates ATF4\/LPLA2-mediated BMP metabolism to enhance HBV-induced hepatocellular carcinogenesis","volume":"84","author":"Zhou","year":"2026","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.iliver.2026.100235_bib67","article-title":"Risk factors for hepatocellular carcinoma: an umbrella review of systematic review and meta-analysis","volume":"57","author":"Wang","year":"2025","journal-title":"Ann Med"},{"issue":"4","key":"10.1016\/j.iliver.2026.100235_bib68","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1017\/S0029665111000565","article-title":"Fats, inflammation and insulin resistance: insights to the role of macrophage and T-cell accumulation in adipose tissue","volume":"70","author":"Harford","year":"2011","journal-title":"Proc Nutr Soc"},{"key":"10.1016\/j.iliver.2026.100235_bib69","doi-asserted-by":"crossref","DOI":"10.1016\/j.tox.2023.153652","article-title":"Synergism in actions of HBV with aflatoxin in cancer development","volume":"499","author":"Jin","year":"2023","journal-title":"Toxicology"},{"issue":"4","key":"10.1016\/j.iliver.2026.100235_bib70","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s12072-020-10031-3","article-title":"Incidence and predictors of hepatocellular carcinoma beyond year 5 of entecavir therapy in chronic hepatitis B patients","volume":"14","author":"Sou","year":"2020","journal-title":"Hepatol Int"},{"issue":"1","key":"10.1016\/j.iliver.2026.100235_bib71","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1053\/j.gastro.2014.03.048","article-title":"Association of nucleos(t)ide analogue therapy with reduced risk of hepatocellular carcinoma in patients with chronic hepatitis B: a nationwide cohort study","volume":"147","author":"Wu","year":"2014","journal-title":"Gastroenterology"},{"issue":"12","key":"10.1016\/j.iliver.2026.100235_bib72","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1136\/gutjnl-2013-306409","article-title":"Patients with chronic hepatitis B treated with oral antiviral therapy retain a higher risk for HCC compared with patients with inactive stage disease","volume":"63","author":"Cho","year":"2014","journal-title":"Gut"},{"issue":"2","key":"10.1016\/j.iliver.2026.100235_bib73","doi-asserted-by":"crossref","first-page":"271","DOI":"10.14309\/ajg.0000000000000428","article-title":"Tenofovir versus entecavir for hepatocellular carcinoma prevention in an international consortium of chronic hepatitis B","volume":"115","author":"Hsu","year":"2020","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"10.1016\/j.iliver.2026.100235_bib74","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.28210","article-title":"Risk factors for hepatocellular carcinoma at baseline and 1 year after initiation of nucleos(t)ide analog therapy for chronic hepatitis B","volume":"95","author":"Kaneko","year":"2023","journal-title":"J Med Virol"},{"issue":"4","key":"10.1016\/j.iliver.2026.100235_bib75","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/jvh.13805","article-title":"Effect of fatty liver and fibrosis on hepatocellular carcinoma development in patients with chronic hepatitis B who received nucleic acid analog therapy","volume":"30","author":"Keitoku","year":"2023","journal-title":"J Viral Hepat"},{"issue":"3","key":"10.1016\/j.iliver.2026.100235_bib76","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1002\/hep.510290312","article-title":"Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection","volume":"29","author":"Lin","year":"1999","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.iliver.2026.100235_bib77","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/S0168-8278(00)00094-5","article-title":"The long-term outcome of interferon-alpha treated and untreated patients with HBeAg-negative chronic hepatitis B","volume":"34","author":"Papatheodoridis","year":"2001","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.iliver.2026.100235_bib78","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jhep.2006.08.021","article-title":"Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma","volume":"46","author":"Lin","year":"2007","journal-title":"J Hepatol"},{"issue":"6","key":"10.1016\/j.iliver.2026.100235_bib79","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1159\/000343068","article-title":"Effect of response to interferon-\u03b1 therapy on the occurrence of hepatocellular carcinoma in patients with chronic hepatitis B","volume":"30","author":"Lee","year":"2012","journal-title":"Dig Dis"},{"issue":"6","key":"10.1016\/j.iliver.2026.100235_bib80","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1093\/infdis\/jiv547","article-title":"Peginterferon is superior to nucleos(t)ide analogues for prevention of hepatocellular carcinoma in chronic hepatitis B","volume":"213","author":"Liang","year":"2016","journal-title":"J Infect Dis"},{"issue":"Suppl 1","key":"10.1016\/j.iliver.2026.100235_bib81","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/jvh.12755","article-title":"Peginterferon is preferable to entecavir for prevention of unfavourable events in patients with HBeAg-positive chronic hepatitis B: a five-year observational cohort study","volume":"24","author":"Li","year":"2017","journal-title":"J Viral Hepat"},{"issue":"10","key":"10.1016\/j.iliver.2026.100235_bib82","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1080\/14712598.2018.1518423","article-title":"Interferon-based treatment is superior to nucleos(t)ide analog in reducing HBV-related hepatocellular carcinoma for chronic hepatitis B patients at high risk","volume":"18","author":"Ren","year":"2018","journal-title":"Expert Opin Biol Ther"},{"issue":"3","key":"10.1016\/j.iliver.2026.100235_bib83","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1002\/cncr.33949","article-title":"Entecavir combined with interferon-\u03b1 is superior to entecavir monotherapy in reducing hepatic and extrahepatic cancer in patients with chronic hepatitis B","volume":"128","author":"Cheng","year":"2022","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.iliver.2026.100235_bib84","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinre.2021.101758","article-title":"Comparison of Interferon-\u03b1-based therapy and nucleos(t)ide analogs in preventing adverse outcomes in patients with chronic hepatitis B","volume":"46","author":"Mao","year":"2022","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"10.1016\/j.iliver.2026.100235_bib85","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2024.105892","article-title":"Interim analysis of the PARADISE study: benefits of add-on peginterferon-\u03b1 in NA-treated patients with CHB","volume":"226","author":"Jiang","year":"2024","journal-title":"Antivir Res"},{"issue":"3","key":"10.1016\/j.iliver.2026.100235_bib86","doi-asserted-by":"crossref","first-page":"e801","DOI":"10.1093\/cid\/ciac383","article-title":"Effect of antiviral treatment on hepatitis B virus integration and hepatocyte clonal expansion","volume":"76","author":"Chow","year":"2023","journal-title":"Clin Infect Dis"},{"issue":"Supp 1","key":"10.1016\/j.iliver.2026.100235_bib87","doi-asserted-by":"crossref","first-page":"S195","DOI":"10.1016\/S0168-8278(24)00820-1","article-title":"Peginterferon alpha-2b combined with TDF promotes durable HBsAg loss in patients with chronic hepatitis B: a multicenter, randomized controlled, phase 3 clinical trial","volume":"80","author":"Wang","year":"2024","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.iliver.2026.100235_bib88","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0158297","article-title":"Pegylated interferon \u03b1-2a triggers NK-cell functionality and specific T-cell responses in patients with chronic HBV infection without HBsAg seroconversion","volume":"11","author":"Bruder Costa","year":"2016","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.iliver.2026.100235_bib89","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000098","article-title":"Immune drivers of HBsAg loss in HBeAg-negative CHB patients after stopping nucleotide analog and administration of Peg-IFN","volume":"7","author":"Islam","year":"2023","journal-title":"Hepatol Commun"},{"issue":"1","key":"10.1016\/j.iliver.2026.100235_bib90","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1038\/s41392-021-00776-0","article-title":"Restoration of HBV-specific CD8+ T-cell responses by sequential low-dose IL-2 treatment in non-responder patients after IFN-\u03b1 therapy","volume":"6","author":"Wang","year":"2021","journal-title":"Signal Transduct Targeted Ther"},{"issue":"5","key":"10.1016\/j.iliver.2026.100235_bib91","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/j.jhep.2014.11.031","article-title":"Incidence of hepatocellular carcinoma after HBsAg seroclearance in chronic hepatitis B patients: a need for surveillance","volume":"62","author":"Kim","year":"2015","journal-title":"J Hepatol"},{"issue":"11","key":"10.1016\/j.iliver.2026.100235_bib92","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1111\/apt.13621","article-title":"Nested case-control study: hepatocellular carcinoma risk after hepatitis B surface antigen seroclearance","volume":"43","author":"Gounder","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.iliver.2026.100235_bib93","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/j.jhep.2017.06.019","article-title":"Impact of age and gender on risk of hepatocellular carcinoma after hepatitis B surface antigen seroclearance","volume":"67","author":"Yip","year":"2017","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.iliver.2026.100235_bib94","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.jhep.2018.10.014","article-title":"HBsAg seroclearance further reduces hepatocellular carcinoma risk after complete viral suppression with nucleos(t)ide analogues","volume":"70","author":"Yip","year":"2019","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.iliver.2026.100235_bib95","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1111\/apt.16174","article-title":"Similarly low risk of hepatocellular carcinoma after either spontaneous or nucleos(t)ide analogue-induced hepatitis B surface antigen loss","volume":"53","author":"Yip","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.iliver.2026.100235_bib96","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.jhep.2022.11.020","article-title":"Risk of hepatic decompensation but not hepatocellular carcinoma decreases over time in patients with hepatitis B surface antigen loss","volume":"78","author":"Yip","year":"2023","journal-title":"J Hepatol"},{"issue":"12","key":"10.1016\/j.iliver.2026.100235_bib97","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1111\/apt.13634","article-title":"Systematic review with meta-analysis: development of hepatocellular carcinoma in chronic hepatitis B patients with hepatitis B surface antigen seroclearance","volume":"43","author":"Liu","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.iliver.2026.100235_bib98","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.cgh.2020.05.041","article-title":"Association between seroclearance of hepatitis B surface antigen and long-term clinical outcomes of patients with chronic hepatitis B virus infection: systematic review and meta-analysis","volume":"19","author":"Anderson","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.iliver.2026.100235_bib99","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1111\/jvh.13471","article-title":"Durability of hepatitis B surface antigen seroclearance and subsequent risk for hepatocellular carcinoma: a meta-analysis","volume":"28","author":"Song","year":"2021","journal-title":"J Viral Hepat"},{"issue":"1","key":"10.1016\/j.iliver.2026.100235_bib100","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/apt.16659","article-title":"Systematic review with meta-analysis: the impact of functional cure on clinical outcomes in patients with chronic hepatitis B","volume":"55","author":"Vittal","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"issue":"Suppl","key":"10.1016\/j.iliver.2026.100235_bib101","doi-asserted-by":"crossref","first-page":"S134","DOI":"10.3350\/cmh.2024.0780","article-title":"Update on the treatment navigation for functional cure of chronic hepatitis B: expert consensus 2.0","volume":"31","author":"Wu","year":"2025","journal-title":"Clin Mol Hepatol"},{"issue":"10","key":"10.1016\/j.iliver.2026.100235_bib102","first-page":"977","article-title":"Chinese expert consensus on clinical practice of chronic hepatitis B functional (clinical) cure","volume":"33","year":"2025","journal-title":"Chin J Hepatol"}],"container-title":["iLIVER"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772947826000198?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772947826000198?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T23:26:19Z","timestamp":1781825179000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772947826000198"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":102,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S2772947826000198"],"URL":"https:\/\/doi.org\/10.1016\/j.iliver.2026.100235","relation":{},"ISSN":["2772-9478"],"issn-type":[{"value":"2772-9478","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Functional cure for chronic hepatitis B on hepatocellular carcinoma prevention: Evidence and clinical implications","name":"articletitle","label":"Article Title"},{"value":"iLIVER","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.iliver.2026.100235","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd on behalf of Tsinghua University Press.","name":"copyright","label":"Copyright"}],"article-number":"100235"}}